BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 30953353)

  • 1. CBP/p300 antagonises EGFR-Ras-Erk signalling and suppresses increased Ras-Erk signalling-induced tumour formation in mice.
    Ichise T; Yoshida N; Ichise H
    J Pathol; 2019 Sep; 249(1):39-51. PubMed ID: 30953353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Making sense of Cbp/p300 loss of function mutations in skin tumorigenesis.
    Anastasi S; Alemà S; Segatto O
    J Pathol; 2020 Jan; 250(1):3-6. PubMed ID: 31397888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PTEN loss and activation of K-RAS and β-catenin cooperate to accelerate prostate tumourigenesis.
    Jefferies MT; Cox AC; Shorning BY; Meniel V; Griffiths D; Kynaston HG; Smalley MJ; Clarke AR
    J Pathol; 2017 Dec; 243(4):442-456. PubMed ID: 29134654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double null cells reveal that CBP and p300 are dispensable for p53 targets p21 and Mdm2 but variably required for target genes of other signaling pathways.
    Kasper LH; Thomas MC; Zambetti GP; Brindle PK
    Cell Cycle; 2011 Jan; 10(2):212-21. PubMed ID: 21220944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-targeting BET, CBP, and p300 inhibits neuroendocrine signalling in androgen receptor-null prostate cancer.
    Choo N; Keerthikumar S; Ramm S; Ashikari D; Teng L; Niranjan B; Hedwards S; Porter LH; Goode DL; Simpson KJ; Taylor RA; Risbridger GP; Lawrence MG
    J Pathol; 2024 Jun; 263(2):242-256. PubMed ID: 38578195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The p300 and CBP Transcriptional Coactivators Are Required for β-Cell and α-Cell Proliferation.
    Wong CK; Wade-Vallance AK; Luciani DS; Brindle PK; Lynn FC; Gibson WT
    Diabetes; 2018 Mar; 67(3):412-422. PubMed ID: 29217654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MET signaling in keratinocytes activates EGFR and initiates squamous carcinogenesis.
    Cataisson C; Michalowski AM; Shibuya K; Ryscavage A; Klosterman M; Wright L; Dubois W; Liu F; Zhuang A; Rodrigues KB; Hoover S; Dwyer J; Simpson MR; Merlino G; Yuspa SH
    Sci Signal; 2016 Jun; 9(433):ra62. PubMed ID: 27330189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting p300 Addiction in CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of MYC Expression.
    Ogiwara H; Sasaki M; Mitachi T; Oike T; Higuchi S; Tominaga Y; Kohno T
    Cancer Discov; 2016 Apr; 6(4):430-45. PubMed ID: 26603525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic interaction between mutations in c-Myb and the KIX domains of CBP and p300 affects multiple blood cell lineages and influences both gene activation and repression.
    Kasper LH; Fukuyama T; Lerach S; Chang Y; Xu W; Wu S; Boyd KL; Brindle PK
    PLoS One; 2013; 8(12):e82684. PubMed ID: 24340053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor immune escape by the loss of homeostatic chemokine expression.
    Pivarcsi A; Müller A; Hippe A; Rieker J; van Lierop A; Steinhoff M; Seeliger S; Kubitza R; Pippirs U; Meller S; Gerber PA; Liersch R; Buenemann E; Sonkoly E; Wiesner U; Hoffmann TK; Schneider L; Piekorz R; Enderlein E; Reifenberger J; Rohr UP; Haas R; Boukamp P; Haase I; Nürnberg B; Ruzicka T; Zlotnik A; Homey B
    Proc Natl Acad Sci U S A; 2007 Nov; 104(48):19055-60. PubMed ID: 18025475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inducible cutaneous inflammation reveals a protumorigenic role for keratinocyte CXCR2 in skin carcinogenesis.
    Cataisson C; Ohman R; Patel G; Pearson A; Tsien M; Jay S; Wright L; Hennings H; Yuspa SH
    Cancer Res; 2009 Jan; 69(1):319-28. PubMed ID: 19118017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TDAG51 is an ERK signaling target that opposes ERK-mediated HME16C mammary epithelial cell transformation.
    Oberst MD; Beberman SJ; Zhao L; Yin JJ; Ward Y; Kelly K
    BMC Cancer; 2008 Jul; 8():189. PubMed ID: 18597688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IKKalpha is required to maintain skin homeostasis and prevent skin cancer.
    Liu B; Xia X; Zhu F; Park E; Carbajal S; Kiguchi K; DiGiovanni J; Fischer SM; Hu Y
    Cancer Cell; 2008 Sep; 14(3):212-25. PubMed ID: 18772111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The ability of E1A to rescue ras-induced premature senescence and confer transformation relies on inactivation of both p300/CBP and Rb family proteins.
    Deng Q; Li Y; Tedesco D; Liao R; Fuhrmann G; Sun P
    Cancer Res; 2005 Sep; 65(18):8298-307. PubMed ID: 16166306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of Smad4 in transformed keratinocytes containing a Ras oncogene leads to hyperactivation of the Ras-dependent Erk signalling pathway associated with progression to undifferentiated carcinomas.
    Iglesias M; Frontelo P; Gamallo C; Quintanilla M
    Oncogene; 2000 Aug; 19(36):4134-45. PubMed ID: 10962574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytoskeleton protein 4.1R suppresses murine keratinocyte cell hyperproliferation via activating the Akt/ERK pathway in an EGFR-dependent manner.
    Chen L; Wang T; Ji X; Ding C; Liang T; Liu X; Lu J; Guo X; Kang Q; Ji Z
    Exp Cell Res; 2019 Nov; 384(2):111648. PubMed ID: 31562860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pro-apoptotic function of iASPP by stabilizing p300 and CBP through inhibition of BRMS1 E3 ubiquitin ligase activity.
    Kramer D; Schön M; Bayerlová M; Bleckmann A; Schön MP; Zörnig M; Dobbelstein M
    Cell Death Dis; 2015 Feb; 6(2):e1634. PubMed ID: 25675294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Lineage-specific MITF Pathway in Human Melanoma Cell Lines by A-485, the Selective Small-molecule Inhibitor of p300/CBP.
    Wang R; He Y; Robinson V; Yang Z; Hessler P; Lasko LM; Lu X; Bhathena A; Lai A; Uziel T; Lam LT
    Mol Cancer Ther; 2018 Dec; 17(12):2543-2550. PubMed ID: 30266801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated levels of ornithine decarboxylase cooperate with Raf/ERK activation to convert normal keratinocytes into invasive malignant cells.
    Hayes CS; DeFeo K; Lan L; Paul B; Sell C; Gilmour SK
    Oncogene; 2006 Mar; 25(10):1543-53. PubMed ID: 16278677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling the transcriptional consequences of epidermal growth factor receptor ablation in Ras-initiated squamous cancer.
    Wright LN; Ryscavage A; Merlino G; Yuspa SH
    Clin Cancer Res; 2012 Jan; 18(1):170-83. PubMed ID: 22068661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.